News Releases

Media Contact: Lissa Pavluk media@apellis.com (617) 977-6764

June 29, 2017 Apellis Pharmaceuticals Announces Positive Data from APL-2 Studies Showing Rapid and Durable Improvements in LDH and Hemoglobin Levels in PNH
March 24, 2017 Apellis Pharmaceuticals Announces Formation of Scientific Advisory Board
March 9, 2017 Apellis Receives EMA Orphan Drug Designation for APL-2 in PNH
February 14, 2017 Apellis Pharmaceuticals Enters Clinical Testing Phase in its Age-Related Macular Degeneration Program
August 8, 2016 Apellis Pharmaceuticals Announces Appointment of Dr. Robert Kim as Chief Medical Officer
June 23, 2016 Apellis Announces Positive Results from Phase 1 Clinical Trials of APL-2, a C3 Complement Inhibitor
July 15, 2015 Apellis Pharmaceuticals Announces Formation of Scientific Advisory Board
February 10, 2015 Apellis Pharmaceuticals Enters Clinical Testing Phase in its Age-Related Macular Degeneration Program
December 2, 2014 Apellis Pharmaceuticals Raises $33M to Fund its Complement Immunotherapy Programs
November 20, 2014 Apellis Pharmaceuticals to acquire Potentia Pharmaceuticals.